Integrated DNA Technologies (IDT), a Danaher company and a global genomics solutions provider, has entered into a strategic collaboration with Ansa Biotechnologies Inc to enhance its synthetic biology portfolio with advanced DNA synthesis capabilities.

Through the collaboration, Ansa’s Clonal DNA and XL Clonal DNA offerings—covering lengths from 100 base pairs to 50 kilobases—will be made available to IDT customers worldwide. The expanded portfolio will allow researchers to design and assemble longer and more complex DNA constructs, supporting applications across cell and gene therapy discovery, vaccine development, and agrigenomics.

The partnership enables customers to access sequence-verified DNA constructs up to 50 kb, addressing a critical need as biological research increasingly demands higher complexity and precision. By combining IDT’s nearly four decades of quality, service excellence, and global reach with Ansa’s proprietary enzymatic DNA synthesis platform, the collaboration aims to establish a new benchmark for speed, accuracy, and reliability in synthetic biology.

Each DNA sequence delivered through the collaboration undergoes rigorous verification and optimization for challenging elements such as GC content, homopolymers, and repetitive regions, reducing downstream risk, minimizing rework, and accelerating research timelines.

Ajay Gannerkote, president of Integrated DNA Technologies, said the collaboration reflects IDT’s commitment to simplifying increasingly complex research challenges. He noted that pairing IDT’s trusted infrastructure with Ansa’s innovation enables researchers to rely on a single partner across all levels of DNA complexity, helping drive meaningful scientific breakthroughs.

Jason T. Gammack, chief executive officer of Ansa Biotechnologies, said the company was founded to overcome fundamental limitations in DNA synthesis related to length, complexity, and reliability. He added that the collaboration with IDT removes long-standing technical barriers and empowers researchers worldwide to advance ambitious scientific programs with greater confidence.

Ansa’s enzymatic DNA synthesis platform enables the production of long, complex DNA sequences without the use of harsh chemicals, preserving DNA integrity while supporting scalable manufacturing. All Ansa DNA products are manufactured in the United States and are designed to integrate seamlessly into existing research workflows. The company operates under a rigorous biosecurity framework and complies fully with the US Office of Science and Technology Policy guidelines for nucleic acid synthesis screening.

Integrated DNA Technologies has evolved from an oligonucleotide manufacturer into a leading genomics solutions provider, working closely with scientific and global health partners to enable discoveries at scale. Through continued innovation and strategic collaborations, IDT aims to help researchers move more rapidly from laboratory insights to real-world impact.